BACKGROUND: Fungi have been developing resistance and merit greater attention because these microorganisms are among the major causes of hospital infection. OBJECTIVE: The aim of the present study was to characterize the pattern of fluconazole use in an adult intensive care unit. SETTING: The setting was an intensive care unit at a university hospital in Brazil. METHOD: An observational retrospective study was performed between 2007 and 2010. The use of antifungal drugs was calculated as the defined daily dose per 1,000 patient-days. The pattern of fluconazole use was determined by analyzing patient charts. RESULTS: Fluconazole accounted an average of 66.6 % of the antifungal agents prescribed. All of the patients exhibited important risk factors for the development of fungal infection. Treatment was empirical in 45.2 % of the cases and therapeutic in 54.8 % of the cases. The dose interval was inadequate in 51.1 % of the treatments. Fluconazole at doses ≥400 mg/day was related to a greater likelihood of survival. C. albicans was the most prevalent species (31.3 %). Urine was the biological material with the greatest number of positive mycological exams (71.9 %). CONCLUSION: This study found a high utilization of fluconazole and, in most cases, its administration at intervals that were different from the recommended intervals.
BACKGROUND: Fungi have been developing resistance and merit greater attention because these microorganisms are among the major causes of hospital infection. OBJECTIVE: The aim of the present study was to characterize the pattern of fluconazole use in an adult intensive care unit. SETTING: The setting was an intensive care unit at a university hospital in Brazil. METHOD: An observational retrospective study was performed between 2007 and 2010. The use of antifungal drugs was calculated as the defined daily dose per 1,000 patient-days. The pattern of fluconazole use was determined by analyzing patient charts. RESULTS:Fluconazole accounted an average of 66.6 % of the antifungal agents prescribed. All of the patients exhibited important risk factors for the development of fungal infection. Treatment was empirical in 45.2 % of the cases and therapeutic in 54.8 % of the cases. The dose interval was inadequate in 51.1 % of the treatments. Fluconazole at doses ≥400 mg/day was related to a greater likelihood of survival. C. albicans was the most prevalent species (31.3 %). Urine was the biological material with the greatest number of positive mycological exams (71.9 %). CONCLUSION: This study found a high utilization of fluconazole and, in most cases, its administration at intervals that were different from the recommended intervals.
Authors: Stefanie Swoboda; Christoph Lichtenstern; Michael Christoff Ober; Lenka Alexandra Taylor; Dominic Störzinger; André Michel; Angelika Brobeil; Markus Mieth; Stefan Hofer; Hans-Günther Sonntag; Torsten Hoppe-Tichy; Markus Alexander Weigand Journal: Chemotherapy Date: 2009-12-08 Impact factor: 2.544
Authors: S Natsch; M H Steeghs; Y A Hekster; J F Meis; J W van der Meer; B J Kullberg Journal: J Antimicrob Chemother Date: 2001-08 Impact factor: 5.790
Authors: H Y Yap; K M Kwok; Charles D Gomersall; S C Fung; T C Lam; P N Leung; Mamie Hui; Gavin M Joynt Journal: Hong Kong Med J Date: 2009-08 Impact factor: 2.227
Authors: P De Bellis; M Bonfiglio; G Gerbi; P Bacigalupo; G Buscaglia; P Guido; B Massobrio Journal: Minerva Anestesiol Date: 2003-03 Impact factor: 3.051
Authors: Peter G Pappas; Carol A Kauffman; David Andes; Daniel K Benjamin; Thierry F Calandra; John E Edwards; Scott G Filler; John F Fisher; Bart-Jan Kullberg; Luis Ostrosky-Zeichner; Annette C Reboli; John H Rex; Thomas J Walsh; Jack D Sobel Journal: Clin Infect Dis Date: 2009-03-01 Impact factor: 9.079
Authors: Melyssa Negri; Tânia P Salci; Cristiane S Shinobu-Mesquita; Isis R G Capoci; Terezinha I E Svidzinski; Erika Seki Kioshima Journal: Molecules Date: 2014-03-07 Impact factor: 4.411